Navigation Links
The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022
Date:12/12/2013

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will decrease from $21.4 billion in 2012 to $18.3 billion in 2017, but will recover to $21.6 billion by 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"The sales pattern in the total chronic pain market is attributable to the loss of market exclusivity for key chronic pain therapies, including controlled-release oxycodone (Purdue Pharma/Mundipharma/Napp Pharmaceuticals' OxyContin), over the next five years," said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. "Market contraction in the first half of the forecast period will be followed by a growth in sales from 2017 through 2022, driven by the launches of a number of emerging therapies."

The Pharmacor report entitled Chronic Pain also finds that the pipeline of therapies in clinical development for chronic pain conditions continues to be composed largely of reformulations of existing molecules—however, agents with novel mechanisms of action, such as subtype-selective sodium channel blockers and monoclonal antibodies against nerve growth factor (NGF), have made recent and notable developmental advances. Overcoming delays due to safety concerns, anti-NGF therapies such as Eli Lilly/Pfizer's tanezumab and Johnson & Johnson/Takeda's fulranumab are forecast to garner significant sales from use in patients with severe, treatment-refractory osteoarthritis pain or chronic low back pain. This class will comprise 19 percent of major-market sales for chronic pain therapies by 2022.

The report also highlights that effective analgesics with lower risk of tolerance and abuse remains a key area of unmet need in this market. Now that the FDA has established a regulatory path for abuse-deterrent, long-acting and extended-release opioids, several abuse-deterrent products from developers including Pfizer, Teva and Purdue are expected to launch in the United States over the next five years. In 2022, sales of abuse-deterrent opioid formulations attributed to chronic pain treatment will exceed $1 billion across the multiple chronic pain indications covered in the report.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
2. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
3. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
4. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
5. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
6. Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. West to Co-present Research Findings on Understanding the Patient Journey through the Phases of a Chronic Disease
8. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
9. Is Chronic Pain Keeping You Awake? Help Is On the Way
10. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
11. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
Breaking Medicine Technology:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global ... Park on Sunday, with sunny skies, a light breeze and temperatures in the 60s. ... , The 5k Run and Walk and 1-mile walk were held to increase ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
Breaking Medicine News(10 mins):